# Aducanumab

Source: https://onco.cc/drugs/da-aducanumab/  
OnCo record `da-aducanumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Aducanumab was an amyloid antibody whose US Alzheimer’s indication was later withdrawn. It is historical context, not a current option.

## Summary

ENGAGE did not meet its primary endpoint as designed. The product is listed so a past approval is not confused with present availability.

## Fields

- Kind: Treatment
- Status: withdrawn
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Brand: Aduhelm
- Modality: mAb
- Mechanism: Amyloid-beta–directed antibody. The US Alzheimer’s indication was withdrawn in 2024.

## Sources

- FDA withdrawn accelerated approvals: https://www.fda.gov/drugs/accelerated-approval-program/withdrawn-non-malignant-hematological-neurological-and-other-disorder-indications-accelerated

## Connected records

- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)
- companies: [Biogen](https://onco.cc/companies/da-biogen/)
- trials: [ENGAGE](https://onco.cc/trials/da-trial-engage/)
- technologies: [Anti-amyloid antibodies](https://onco.cc/technologies/da-tech-anti-amyloid-mab/)
- roadmaps: [Anti-amyloid medicines](https://onco.cc/roadmaps/da-roadmap-anti-amyloid/)

---
JSON: https://onco.cc/api/v1/entities/da-aducanumab.json